Show simple item record

dc.contributor.authorTurner, N
dc.contributor.authorTelli, M
dc.contributor.authorRugo, H
dc.contributor.authorMailliez, A
dc.contributor.authorEttl, J
dc.contributor.authorGrischke, E
dc.contributor.authorMina, L
dc.contributor.authorBalmana, J
dc.contributor.authorFasching, P
dc.contributor.authorHurvitz, S
dc.contributor.authorWardley, Andrew M
dc.contributor.authorChappey, C
dc.contributor.authorHannah, A
dc.contributor.authorRobson, M
dc.date.accessioned2019-02-08T15:20:09Z
dc.date.available2019-02-08T15:20:09Z
dc.date.issued2018en
dc.identifier.citationTurner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Clin Cancer Res. 2018 Dec 18.en
dc.identifier.pmid30563931en
dc.identifier.doi10.1158/1078-0432.CCR-18-1891en
dc.identifier.urihttp://hdl.handle.net/10541/621531
dc.description.abstractPURPOSE: To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced breast cancer (aBC). EXPERIMENTAL DESIGN: ABRAZO (NCT02034916) was a two-cohort, two-stage, phase II study of talazoparib (1 mg/day) in germline BRCA mutation carriers with a response to prior platinum with no progression on or within 8 weeks of the last platinum dose (cohort 1) or ?3 platinum-free cytotoxic regimens (cohort 2) for aBC. Primary endpoint was confirmed objective response rate (ORR) by independent radiological assessment. RESULTS: We enrolled 84 patients (cohort 1, n = 49; cohort 2, n = 35) from May 2014 to February 2016. Median age was 50 (range, 31-75) years. Triple-negative breast cancer incidence was 59% (cohort 1) and 17% (cohort 2). Median number of prior cytotoxic regimens for aBC was two and four, respectively. Confirmed ORR was 21% (95% CI, 10 to 35) (cohort 1) and 37% (95% CI, 22 to 55) (cohort 2). Median duration of response was 5.8 and 3.8 months, respectively. Confirmed ORR was 23% (BRCA1), 33% (BRCA2), 26% (TNBC) and 29% (hormone receptor positive). The most common allgrade adverse events (AEs) included anemia (52%), fatigue (45%), and nausea (42%). Talazoparib-related AEs led to drug discontinuation in three (4%) patients. In an exploratory analysis, longer platinum-free interval was associated with higher response rate in cohort 1 (0% ORR with interval <8 weeks; 47% ORR with interval >6 months). CONCLUSIONS: Talazoparib exhibited promising antitumor activity in patients with aBC and germline BRCA mutation.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1078-0432.CCR-18-1891en
dc.titleA phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO)en
dc.typeArticleen
dc.contributor.departmentBreast Cancer Now Research Centre, Institute of Cancer Research and The Royal Marsden Hospitalen
dc.identifier.journalClincal Cancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record